在2x2交叉設計下進行藥物動力學(pharmacokinetic)的研究中，本文考慮以直接比較平均藥物濃度-時間側寫(drug concentration-time profile)的角度評估參照藥品與測試藥品的平均生物相等性(average bioequivalence)。本文首先假設藥物濃度服從廣義伽瑪分配，在平均藥物濃度-時間側寫為一階單區藥物動力模式(one-compartment model)下提出藥物濃度的參數藥物動力學模型。除收集藥物濃度資料外，亦包含與受試者生理狀態相關的共變數，本文在參數藥物動力學模型中考慮引入線性共變數效應解釋受試者之間的差異性。本文進一步考慮半參數藥物動力學模型，在不假設特定藥物動力學模式下，以自然立方樣條估計(natural cubic spline)平均藥物濃度-時間側寫，並考慮非線性共變數效應及共變數之間的交互作用。除討論各模型參數之估計、模式評估及應用外，並根據模型估計之平均側寫建構多重生物相等性檢定。本文使用蒙地卡羅(Monte Carlo)方法模擬各種實務中參照藥品及測試藥品的藥物濃度-時間側寫可能出現的情況，以及不同的藥物濃度分配，藉以研究本文所提多重檢定的型一誤差率及檢定力的表現。最後，藉分析兩筆生物相等性研究的資料說明本文所提各種方法的應用。

To evaluate globally the average bioequivalence of a test drug to a reference drug in a pharmacokinetic study under a 2x2 crossover design, we consider directly comparing the associated drug concentration-time curves. Statistical models for the drug concentrations are suggested when the concentrations measured at different time points are distributed according to a generalized gamma distribution and the mean concentrations over time are described by a one-compartment pharmacokinetic model. A multiple test based on the supreme distance between the two curves over the time interval under study is then proposed for testing the equivalence of the two drug concentration-time curves. We also propose a semi-parametric model for drug concentrations in blood or plasma over time. The semi-parametric model primarily includes smooth mean drug concentration-time curves that can be estimated by using natural cubic splines. Based on the difference of the two estimated natural cubic splines, we then suggest a test for the bioequivalence of the two drugs. The robustness of the level and power performances of the suggested tests are further investigated in a simulation study. Finally, we illustrate two datasets for the bioequivalence study by using the proposed models and tests.

Anderson, S. and Hauck, W. W. (1990). Consideration of individual bioequivalence. Journal of Pharmacokinetics and Biopharmaceutics 18, 259-273.
Berger, R. L. (1982). Multiparameter hypothesis testing and acceptance sampling. Technometrics 24, 295-300.
Berger, R. L. and Hsu, J. C. (1996). Bioequivalence trials, intersection-union tests and equivalence confidence sets. Statistical Science 11, 283-319.
Brown, L. D., Casella, G. and Huang, J. T. G. (1995). Optimal confidence sets, bioequivalence, and limaçon of Pascal. Journal of the American Statistical Association 90, 880-889.
Brown, L. D., Huang, J. T. G. and Munk, A. (1997). An unbiased test for the bioequivalence problem. The Annals of Statistics 6, 2345-2367.
Chow, C.-S. and Liu, J.-P. (2008). Design and analysis of bioavailability and bioequivalence studies. Marcel Dekker, New York.
Durrleman, S. and Simon, R. (1989). Flexible regression-models with cubic-splines. Statistics in Medicine 8, 551-561.
Efron, B. (1981). Nonparametric estimates of standard error : the jackknife, the bootstrap, and other methods. Biometrika 68, 589-599.
Efron, B. (1987). Better bootstrap confidence intervals. Journal of the American Statistical Association 82, 171-185.
Efron, B. and Tibshirani, R. (1986). Bootstrap methods for standard errors, confidence intervals, and other measures of statistical accuracy. Statistical Science 1, 54-75.
Food and Drug Administration (1992). Guidance on statistical procedures for bioequivalence studies using a standard two-treatment crossover design. Division of Bioequivalence, Rockville, MD.
Food and Drug Administration (2001). Guidance for industry: statistical approaches to establishing bioequivalence. Center for Drug Evaluation and Research, Rockville, MD.
Food and Drug Administration (2003). Guidance for industry: bioavailability and bioequivalence studies for orally administered drug product－general considerations. Center for Drug Evaluation and Research, Rockville, MD.
Hauck, W. W., Hyslop, T., Anderson, S., Bois, F. Y. and Tozer, T. N. (1995). Statistical and regulatory considerations for multiple measures in bioequivalence testing. Clinical Research and Regulatory Affairs 12, 249-265.
Hauck, W. W. and Anderson, S. (1992). Types of bioequivalence and related statistical considerations. International Journal of Clinical Pharmacology, Therapy and Toxicology 30, 181-187.
Hsu, J. C., Huang, J. T. G., Liu, H.-K. and Ruberg, S. J. (1994). Confidence intervals associated with tests for bioequivalence. Biometrika 81, 103-114.
Ihaka, R. and Gentleman, R. (1996). R: A language for data analysis and graphics. Journal of Computational and Graphical Statistics 5, 299-314.
Liao, J. Z. (2005). Comparing the concentration curves directly in a pharmacokinetics, bioavailability/bioequivalence study. Statistics in Medicine 24, 883-891.
Lindsey, J. K., Byrom, W. D., Wang, J., Jarvis, P. and Jones, B. (2000). Generalized nonlinear models for pharmacokinetic data. Biometrics 56, 30-36.
Liu, J.-P. and Chow, C.-S. (1992). On the assessment of variability in bioavailability/bioequivalence studies. Communications in Statistics-Theory Methods 21, 2591-2607.
MacEachern, S. N. and Müeller, P. (1998). Estimating mixtures of Dirichlet process models. Journal of Computational and Graphical Statistics 7, 223–338.
Massey, F. J., Jr. (1951). The Kolmogorov-Smirnov test of goodness of fit. Journal of the American Statistical Association 46, 68-78.
Munk, A. and Pflüger, R. (1999). 1-alpha equivalence rules for convex alternatives are alpha/2-level tests－with applications to the multivariate assessment of bioequivalence. Journal of the American Statistical Association 94, 1311-1319.
Rowland, M. and Tozer, T. N. (1994). Clinical pharmacokinetics, concepts and applications. Williams and Wilkins, Baltimore.
Salway, R. and Wakefield, J. (2007). Gamma generalized linear models for pharmacokinetic data. Biometrics 64, 620-626.
Schuirmann, D. L. (1981). On hypothesis testing to determine if the mean of a normal distribution in contained in a known interval. Biometrics 37, 617.
Stacy, E.W. (1962). A generalization of the gamma distribution. Annals of Mathematical Statistics 33, 1187-1192.
Stone, C. J. (1994). The use of polynomial splines and their tensor products in multivariate function estimation (with discussion). The Annals of Statistics 22, 118-184.
Wagner J. G. (1993). Pharmacokinetics for the Pharmaceutical Scientist. Technomic: Pennsylvania.
Wang, W., Hwang, J. T. G. and Dasgupta, A. (1999). Statistical tests for multivariate bioequivalence. Biometrika 86, 395-402.
Wellek, S. (1993). Basing the analysis of comparative bioavailability trials on an individualized statistical definition of equivalence. Biometrical journal 35, 47-55.
Westlake, W. J. (1972). Use of confidence intervals in analysis of comparative bioavailability trials. Journal of Pharmaceutics Sciences 61, 1340-1341.
Westlake, W. J. (1981). Response to T.B.L. Kirkwood: bioequivalence testing－a need to rethink. Biometrics 37, 589-594.
Westlake, W. J. (1988). Bioavailability and bioequivalence of pharmaceutical formulations. In Biopharmaceutical Statistics for Drug Development (Karl E. peace, ed.) 329-352. Dekker, New York.
Yafune, A. and Ishiguro, M. (1999a). Bootstrap approach for constructing confidence　intervals for population pharmacokinetic parameters. I: A use of Bootstrap standard error. Statistics in Medicine 18, 581-599.
Yafune, A. and Ishiguro, M. (1999b). Bootstrap approach for constructing confidence　intervals for population pharmacokinetic parameters. II: A Bootstrap modification of　standard two-stage method for Phase I trial. Statistics in Medicine 18, 601-612.
Yafune, A. and Ishiguro, M. (2003). A simulation-based confidence band for drug　concentrations in blood: an application to a clinical phase I trial. Statistics in Medicine 22,　3045-3053.
黃慧雯，「雙向交叉設計下生物相等性的多元檢定」，國立中央大學，碩士論文，民國98年。